Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Becton, Dickinson and Company (BD) is a global medical technology company operating across three segments: BD Medical (medication delivery, diabetes care), BD Life Sciences (specimen management, diagnostics), and BD Interventional (surgery, peripheral intervention). With $21.8B in revenue and operations in 190+ countries, BD holds leading positions in safety-engineered syringes, pre-filled drug delivery systems, and microbiology diagnostics. The stock trades at depressed multiples (-20% YoY) despite solid FCF generation ($2.7B), reflecting concerns about hospital procedure volumes, capital equipment spending cycles, and margin compression from input cost inflation.
BD generates revenue through a razor-razorblade model in many segments: capital equipment placements (flow cytometers, automated microbiology systems) drive recurring consumables revenue (reagents, test kits, collection tubes). The medication delivery business benefits from hospital formulary lock-in and regulatory requirements for safety-engineered devices. Pricing power stems from FDA clearances, installed base switching costs, and clinical evidence demonstrating infection reduction. Gross margins of 45.4% reflect manufacturing scale in high-volume consumables (billions of syringes annually) offset by lower-margin capital equipment. Operating leverage is moderate due to significant R&D investment (6-7% of sales) and global distribution infrastructure.
Hospital procedure volumes and capital equipment spending cycles - elective surgery deferrals directly impact BD Interventional revenue
Medication delivery device adoption rates - safety-engineered syringe mandates, pre-filled drug delivery partnerships with pharma companies
Diagnostics demand trends - COVID testing normalization, respiratory panel volumes, microbiology automation penetration
Margin trajectory - ability to pass through input cost inflation, manufacturing efficiency improvements, product mix shift to higher-margin devices
M&A activity and capital allocation - history of large acquisitions (Bard $24B in 2017), debt paydown priorities, dividend sustainability
Healthcare cost containment pressures - GPO negotiations, value-based care models, and hospital consolidation increasing buyer power and limiting pricing flexibility on commodity products
Regulatory pathway changes - FDA scrutiny on device approvals, EU MDR compliance costs, potential for accelerated generic competition in drug delivery devices
Technology disruption - digital health platforms, point-of-care diagnostics, and AI-enabled pathology potentially disintermedating traditional lab workflows and specimen collection
Intense competition in core markets - Medtronic, Abbott, Danaher (Cepheid molecular diagnostics), Terumo in syringes, driving pricing pressure and share loss in commoditized segments
Pharma vertical integration - large drug manufacturers developing proprietary delivery devices (pre-filled syringes, autoinjectors), bypassing BD's platforms and eroding medication delivery margins
Elevated debt levels from Bard acquisition - $15B gross debt requires $2.5B+ annual FCF for deleveraging targets, limiting M&A flexibility and share repurchase capacity through 2027
Pension obligations and restructuring charges - legacy defined benefit plans and ongoing manufacturing footprint optimization creating cash flow variability
moderate - Hospital procedure volumes correlate with employment levels (elective surgeries deferred during recessions) and healthcare utilization rates. Capital equipment purchases are discretionary and delayed during budget constraints. However, ~40% of revenue from non-discretionary consumables (specimen collection, diabetes care) provides defensive characteristics. International exposure (50%+ of sales) creates sensitivity to global GDP growth, particularly in emerging markets where healthcare infrastructure investment is GDP-linked.
Rising rates create moderate headwinds through two channels: (1) $15B debt load (0.77 D/E) increases interest expense, pressuring margins - each 100bps rate increase adds ~$150M annual interest cost; (2) Hospital capital budgets tighten as financing costs rise, delaying equipment purchases. However, BD's investment-grade rating (A-/Baa1) limits refinancing risk. Valuation multiple compression occurs as healthcare device stocks de-rate when risk-free rates rise (current 16.2x EV/EBITDA vs. historical 18-20x range).
Moderate exposure through hospital customer creditworthiness - BD extends payment terms to health systems, creating receivables risk during financial stress. Tighter credit conditions reduce hospital access to capital for equipment purchases. However, BD's diversified customer base (thousands of hospitals, clinics, labs globally) and short receivables cycle (DSO ~60 days) limit concentration risk. Minimal direct lending exposure.
value - Stock trades at 20% discount to historical multiples (16.2x EV/EBITDA vs. 18-20x) with 5.3% FCF yield, attracting value investors betting on margin recovery and multiple re-rating. Dividend yield (~1.5%) and consistent FCF generation appeal to income-focused healthcare investors. Recent underperformance (-20% YoY) creates contrarian opportunity if procedure volumes normalize and supply chain costs moderate. Not a growth stock given mid-single-digit organic growth profile.
moderate - Beta typically 0.8-0.9 vs. S&P 500, reflecting defensive healthcare characteristics offset by capital equipment cyclicality. Recent volatility elevated due to COVID testing normalization and margin compression concerns. Quarterly earnings volatility driven by capital equipment order timing and FX translation (50% international sales). Less volatile than high-growth med-tech peers but more volatile than pharma due to procedure volume sensitivity.
